Welcome to our dedicated page for TILRAY BRANDS news (Ticker: TLRY), a resource for investors and traders seeking the latest updates and insights on TILRAY BRANDS stock.
TIlray Brands, Inc. (TLRY) generates frequent news as a global lifestyle and consumer packaged goods company active across cannabis, beverage, wellness, and entertainment categories. Company updates often highlight developments in its cannabis brands, medical cannabis operations, beverage portfolio, and strategic corporate actions, giving investors and followers insight into how Tilray is executing its multi-category strategy.
News coverage commonly includes financial results and segment performance across cannabis, beverage, wellness, and distribution, as reflected in Tilray’s quarterly earnings releases. These updates may discuss trends in international medical cannabis revenue, Canadian adult-use cannabis sales, and distribution activity through Tilray Pharma. Corporate announcements, such as the implementation of a one-for-ten reverse stock split and related shareholder decisions, are also reported through press releases and SEC filings.
Tilray’s brand and product news provides detail on new launches and category expansion. Recent communications feature Dry January and holiday guides showcasing hemp-derived THC beverages, zero-proof spirits, non-alcoholic beers, and craft beers, as well as cannabis-infused beverages under brands like Mollo and XMG. Other releases focus on innovations in cannabis vapes and concentrates under brands such as Good Supply and Redecan, and curated cannabis gift guides that reflect consumer trends in Canada.
Regulatory and medical developments are another important theme. Tilray Medical has issued statements on U.S. federal cannabis rescheduling and the creation of Tilray Medical USA, outlining a framework for U.S. medical cannabis expansion based on experience in regulated international markets. For readers tracking TLRY, this news stream offers context on how the company responds to policy changes, evolves its brand portfolio, and communicates with shareholders. Bookmark this page to access an organized feed of Tilray’s earnings releases, product announcements, regulatory updates, and other material company news.
Tilray reported strong financial results for the fourth quarter and full fiscal year ending May 31, 2021. Net revenue surged 25% to $142.2 million in Q4, driven by a 36% increase in cannabis revenue. The company achieved significant cost synergies of $35 million with a target of $80 million in the next 16 months. Adjusted EBITDA soared 285% in Q4, marking the ninth consecutive quarter of positive performance. However, the net loss widened to $336 million for the fiscal year, impacted by transaction costs and unrealized losses. Strong cash reserves of $488.5 million bolster the company's growth strategy.
Manitoba Harvest, a leader in hemp foods, is collaborating with Protein Industries Canada and industry partners to develop enhanced hemp and pea varieties aimed at boosting protein content and texture. This initiative is part of a $5.1 million investment, with Manitoba Harvest and its partners contributing $3.3 million, while Protein Industries Canada adds $1.8 million. The advancements will support the growing demand for plant-based proteins and align with the company's commitment to superior product quality and innovation. Manitoba Harvest is a subsidiary of Tilray (TLRY).
Tilray, Inc. (NASDAQ: TLRY) will release its financial results for the fourth quarter and fiscal year 2021 on July 28, 2021, before market opening. A conference call hosted by executives will take place at 8:30 am Eastern Time to discuss these results. Shareholders can submit questions through Say Technologies prior to the call. Tilray focuses on providing cannabis and consumer packaged goods globally, with a mission to enhance wellbeing through quality products.
Tilray, a leader in cannabis, announced that its German subsidiary, Aphria RX GmbH, successfully harvested medical cannabis in Germany, marking a key milestone for local production and distribution. This is the first harvest under EU Good Manufacturing Practices at their facility in Neumünster. The distribution complies with pharmaceuticals regulations, reducing reliance on imports for Germany's over 100,000 medical cannabis patients. Tilray's CEO emphasized the European market's growth potential, particularly in Germany, as they aim to enhance patient access to high-quality cannabis products.
Tilray has announced a collaboration between SweetWater Brewing Company and Broken Coast Cannabis to launch Broken Coast BC Lager, marking Tilray's first cannabis brand introduction in the U.S. The lager is crafted for beer enthusiasts and highlights the brands' commitment to quality. CEO Irwin D. Simon stated this partnership is a key milestone in their strategy to expand Canadian cannabis brands into the U.S. market. The new lager will be available on draft and in six-pack cans starting July 12, showcasing the growing intersection of cannabis and consumer products.
Tilray (NASDAQ | TSX: TLRY) has released a proxy statement urging shareholders to support key proposals at the Special Meeting scheduled for July 29, 2021. The company seeks to increase authorized shares of common stock to pursue growth through acquisitions and financing opportunities. Additionally, Tilray is proposing amendments to enhance shareholder rights following its merger with Aphria Inc. Shareholders on record as of June 22, 2021, are encouraged to vote by July 28, 2021, to ensure their voices are heard for these critical initiatives.
Tilray, a prominent cannabis-lifestyle company, has launched Symbios, a new medical brand in Canada, designed to enhance its product offerings. Symbios aims to provide a diverse range of formats and cannabinoid ratios at competitive prices, catering to medical patients’ health needs. Alongside this, Tilray introduced high-potency medical cannabis topicals under the Aphria brand targeting inflammatory joint diseases. CEO Irwin D. Simon emphasized innovation and patient care as key components of Tilray's global growth strategy, aiming to build on momentum across its medical brands.
Tilray (NASDAQ: TLRY) announced participation in two investor conferences in June 2021. The first is the Jefferies Virtual Healthcare Conference on June 1 at 8:30 AM ET, followed by the Stifel Cross Sector Insight Conference on June 8 at 4:00 PM ET. Webcast details will be available on the company’s website under the Investors section. Tilray is a pioneering global cannabis and consumer packaged goods company dedicated to enhancing well-being through high-quality products across various markets, including Canada, the US, Europe, and beyond.
Tilray announced its participation in the BMO Capital Markets 16th Annual Farm to Market Conference on May 19, 2021, with a presentation scheduled for 8:40 AM ET. Investors can access the conference details and webcast information through the Tilray website.
Tilray is a leading global cannabis-lifestyle company with operations in multiple regions, committed to enhancing well-being through high-quality products and innovative brands. The company aims to be a trusted partner for consumers, offering over 20 brands across more than 20 countries.
Tilray announced that its class 2 common stock (TLRY) began trading on the Toronto Stock Exchange as of May 5, 2021, while continuing to be listed on the Nasdaq. Following the merger with Aphria, shareholders of Aphria received 0.8381 Tilray Shares for each Aphria Share held as of April 30, 2021. Tilray aims to enhance well-being through its diverse portfolio of over 20 brands across various sectors, including cannabis, hemp, and alcoholic beverages, establishing itself as a leader in the global cannabis market.
FAQ
What is the current stock price of TILRAY BRANDS (TLRY)?
What is the market cap of TILRAY BRANDS (TLRY)?
